• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

发现基于3-酰胺基嘧啶的衍生物作为治疗急性髓性白血病的潜在Fms样酪氨酸受体激酶3(FLT3)抑制剂。

Discovery of 3-amide-pyrimidine-based derivatives as potential fms-like tyrosine receptor kinase 3 (FLT3) inhibitors for treating acute myelogenous leukemia.

作者信息

Liu Wei, Ma Yi, Wang Miaomiao, He Youyou, Liu Yanhong, Zhu Zhenbao, Ding Yi, Zhang Ge, Wang Shengzheng

机构信息

Faculty of Pharmacy, School of Food and Biological Engineering, Shaanxi University of Science and Technology, Xi'an, Shaanxi 710021, China; Department of Medicinal Chemistry and Pharmaceutical Analysis, School of Pharmacy, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.

Faculty of Pharmacy, School of Food and Biological Engineering, Shaanxi University of Science and Technology, Xi'an, Shaanxi 710021, China.

出版信息

Bioorg Med Chem Lett. 2025 Mar 1;117:130082. doi: 10.1016/j.bmcl.2024.130082. Epub 2024 Dec 19.

DOI:10.1016/j.bmcl.2024.130082
PMID:39708925
Abstract

FLT3-ITD and TKD mutants play a central role in acute myeloid leukemia (AML), making FLT3 an attractive target for AML treatment. To discover next-generation FLT3 inhibitors and gather additional structure-activity relationship (SAR) information, we performed structural modifications of G-749 (denfivontinib) utilizing structure simplification and scaffold hopping strategies. Among these derivatives, MY-10 exhibited the most potent and selective inhibition of MV4-11 cell proliferation, demonstrating potent inhibitory activity against FLT3-ITD (IC = 6.5 nM) and FLT3-D835Y (IC = 10.3 nM) mutants. Notably, MY-10 exhibited no inhibitory activity against c-KIT kinase (IC > 100 μM). Mechanistic studies revealed that MY-10 arrested the cell cycle at the G0/G1 phase and efficiently induced apoptosis. Furthermore, it significantly reduced reactive oxygen species (ROS) production and mitochondrial membrane potential (MMP), and strongly inhibited FLT3-mediated signaling pathways. These findings, along with the obtained SAR information, provide valuable insights for the further development of FLT3 inhibitors.

摘要

FLT3内部串联重复(FLT3-ITD)和酪氨酸激酶结构域(TKD)突变体在急性髓系白血病(AML)中起核心作用,这使得FLT3成为AML治疗的一个有吸引力的靶点。为了发现下一代FLT3抑制剂并收集更多的构效关系(SAR)信息,我们利用结构简化和骨架跃迁策略对G-749(登菲凡替尼)进行了结构修饰。在这些衍生物中,MY-10对MV4-11细胞增殖表现出最有效和选择性的抑制作用,对FLT3-ITD(IC = 6.5 nM)和FLT3-D835Y(IC = 10.3 nM)突变体表现出强效抑制活性。值得注意的是,MY-10对c-KIT激酶没有抑制活性(IC > 100 μM)。机制研究表明,MY-10使细胞周期停滞在G0/G1期并有效诱导凋亡。此外,它显著降低活性氧(ROS)的产生和线粒体膜电位(MMP),并强烈抑制FLT3介导的信号通路。这些发现以及获得的SAR信息为FLT3抑制剂的进一步开发提供了有价值的见解。

相似文献

1
Discovery of 3-amide-pyrimidine-based derivatives as potential fms-like tyrosine receptor kinase 3 (FLT3) inhibitors for treating acute myelogenous leukemia.发现基于3-酰胺基嘧啶的衍生物作为治疗急性髓性白血病的潜在Fms样酪氨酸受体激酶3(FLT3)抑制剂。
Bioorg Med Chem Lett. 2025 Mar 1;117:130082. doi: 10.1016/j.bmcl.2024.130082. Epub 2024 Dec 19.
2
Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.发现一种基于苯并咪唑的双 FLT3/TrKA 抑制剂,针对急性髓系白血病。
Bioorg Med Chem. 2022 Feb 15;56:116596. doi: 10.1016/j.bmc.2021.116596. Epub 2021 Dec 30.
3
Discovery of novel 4-azaaryl-N-phenylpyrimidin-2-amine derivatives as potent and selective FLT3 inhibitors for acute myeloid leukaemia with FLT3 mutations.发现新型 4-氮杂芳基-N-苯基嘧啶-2-胺衍生物作为具有 FLT3 突变的急性髓系白血病的有效和选择性 FLT3 抑制剂。
Eur J Med Chem. 2021 Mar 5;213:113215. doi: 10.1016/j.ejmech.2021.113215. Epub 2021 Jan 22.
4
Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases.发现和开发 ITID 和 D835Y 突变型 FLT3 激酶的极端选择性抑制剂。
Eur J Med Chem. 2019 Dec 15;184:111710. doi: 10.1016/j.ejmech.2019.111710. Epub 2019 Oct 5.
5
Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor.基于对 NEK2 抑制剂的结构优化,发现咪唑并[1,2-a]吡啶-噻吩衍生物为 FLT3 和 FLT3 突变体抑制剂,用于治疗急性髓系白血病。
Eur J Med Chem. 2021 Dec 5;225:113776. doi: 10.1016/j.ejmech.2021.113776. Epub 2021 Aug 17.
6
Identification of furo[2,3-d]pyrimidin-4-ylsulfanyl-1,3,4-thiadiazole derivatives as novel FLT3-ITD inhibitors.鉴定呋[2,3-d]嘧啶-4-基硫基-1,3,4-噻二唑衍生物为新型 FLT3-ITD 抑制剂。
Eur J Med Chem. 2024 Dec 15;280:116962. doi: 10.1016/j.ejmech.2024.116962. Epub 2024 Oct 12.
7
Design, synthesis, and biological evaluation of 4-(2-fluorophenoxy)pyridine derivatives as novel FLT3-ITD inhibitors.新型FLT3-ITD抑制剂4-(2-氟苯氧基)吡啶衍生物的设计、合成及生物学评价
Eur J Med Chem. 2025 May 5;289:117492. doi: 10.1016/j.ejmech.2025.117492. Epub 2025 Mar 9.
8
Discovery and structure - activity relationship exploration of pyrazolo[1,5-a]pyrimidine derivatives as potent FLT3-ITD inhibitors.发现和结构-活性关系研究:作为有效 FLT3-ITD 抑制剂的吡唑并[1,5-a]嘧啶衍生物。
Bioorg Med Chem. 2021 Oct 15;48:116422. doi: 10.1016/j.bmc.2021.116422. Epub 2021 Sep 21.
9
Identification of Pyrrolo[2,3- d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia.鉴定吡咯并[2,3- d]嘧啶类衍生物作为有效且可口服的 Fms 样酪氨酸激酶 3(FLT3)抑制剂用于治疗急性髓系白血病。
J Med Chem. 2019 Apr 25;62(8):4158-4173. doi: 10.1021/acs.jmedchem.9b00223. Epub 2019 Apr 15.
10
A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia.一系列新型芳基甲酮衍生物作为 FMS 样酪氨酸激酶 3(FLT3)抑制剂在 FLT3-ITD 阳性急性髓系白血病中的应用。
Eur J Med Chem. 2020 May 1;193:112232. doi: 10.1016/j.ejmech.2020.112232. Epub 2020 Mar 13.